{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:41:32Z","timestamp":1774262492756,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1684\/bdc.2010.1136","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"997-1009","source":"Crossref","is-referenced-by-count":11,"title":["Recommandations du groupe Fi-LMC pour la gestion des effets ind\u00e9sirables du traitement par nilotinib (Tasigna\u00ae) au cours de la leuc\u00e9mie my\u00e9lo\u00efde chronique"],"prefix":"10.1016","volume":"97","author":[{"given":"G.","family":"\u00c9tienne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"R\u00e9a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rigal-Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tulliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-E.","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2010.1136_bib0005","first-page":"863","article-title":"Treatment of chronic myeloid leukemia in 2007","volume":"94","author":"Labussi\u00e8re","year":"2007","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2010.1136_bib0010","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"NEJM"},{"issue":"2","key":"10.1684\/bdc.2010.1136_bib0015","first-page":"255","article-title":"Final safety analysis of 1,793 cml patients from ENACT (expanding nilotinib access in clinical trials) study in adult patients with imatinib-resistant or intolerant Chronic myeloid leukemia","volume":"94","author":"Nicolini","year":"2009","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2010.1136_bib0020","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine-kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1136_bib0025","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph+chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1684\/bdc.2010.1136_bib0030","first-page":"440","article-title":"Nilotinib 800mg daily in early chronic phase chronic myeloid leukemia: 12-month results of a phase II trial of the GIMENA CML working party","volume":"94","author":"Rosti","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1684\/bdc.2010.1136_bib0035","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","article-title":"Practical management of toxicities associated with tyrosine-kinase inhibitors in chronic myeloid leukemia","volume":"8","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1684\/bdc.2010.1136_bib0040","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"10.1684\/bdc.2010.1136_bib0045","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine-kinase inhibitor, is active in patients with imatinib-resistant or intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"Le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1136_bib0050","unstructured":"FDA, prescribing information, ao\u00fbt 2009"},{"key":"10.1684\/bdc.2010.1136_bib0055","unstructured":"RCP nilotinib"},{"key":"10.1684\/bdc.2010.1136_bib0060","unstructured":"RCP dasatinib"},{"key":"10.1684\/bdc.2010.1136_bib0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V112.11.181.181","article-title":"High and early rates of cytogenetic and molecular response with nilotinib 800mg daily as first line treatment of Ph\u2013positive chronic myeloid leukemia in chronic phase: results of a phase II Trial of the GIMEMA CML Working Party","volume":"112","author":"Rosti","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1136_bib0070","series-title":"Williams Hematology","article-title":"Acute myelogenous leukemia","author":"Lichtman","year":"2001"},{"key":"10.1684\/bdc.2010.1136_bib0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-8722-2-42","article-title":"Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study","volume":"2","author":"Conchon","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1684\/bdc.2010.1136_bib0080","first-page":"345","article-title":"No inhibition of warfarin pharmacokinetics and pharmacodynamics by nilotinib in human subjects","volume":"94","author":"Yin","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1684\/bdc.2010.1136_bib0085","first-page":"345","article-title":"Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib","volume":"94","author":"Yin","year":"2009","journal-title":"Haematologica"},{"key":"10.1684\/bdc.2010.1136_bib0090","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood.V112.11.3215.3215","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase or accelerated phase","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1136_bib0095","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1200\/jco.2008.26.15_suppl.7015","article-title":"Dasatinib lack of cross-intolerance to imatinib in patients with chronic myelogenous leukemia chronic phase intolerant to imatinib: a retrospective analysis of safety","volume":"26","author":"Khoury","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1136_bib0100","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to two prior tyrosine-kinase inhibitors (TKI): long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1684\/bdc.2010.1136_bib0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(08)61295-7","article-title":"Dasatinib-induced lupus","volume":"372","author":"Rea","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2010.1136_bib0110","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1136_bib0115","first-page":"805","article-title":"Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias","volume":"95","author":"Cony-Makhoul","year":"2008","journal-title":"Bull Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115307992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115307992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:47:52Z","timestamp":1602492472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115307992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0007455115307992"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2010.1136","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}